Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001869248
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name Phone

E-Mail Address

Address of Issuer

#### 144: Issuer Information

Name of Issuer Aerovate Therapeutics, Inc.

SEC File Number 001-40544

930 WINTER STREET

SUITE M-500 WALTHAM NEW YORK

NEW YC 02451

Phone 617-443-2400

Name of Person for Whose Account the Securities are To Be Sold

Dake Benjamin T

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

### 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Securities
Common Cl A	Jefferies LLC 520 Madison Ave, 4th Floor New York NY 10022	10284	226350.84	24810000	05/08/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

Title of the Name of Person Is Amount of Date of Date you Nature of Date Nature of Class **Acquired** Acquisition from Whom this **Donor Securities Payment** Payment \*

	Transaction	Acquired	a Acquired Gift?	d Acquired	
Common	09/04/2020 Employee Stock Option Exercise	Aerovate Therapeutics, Inc.		2413	09/04/2020 N/A
Common	04/02/2021 Employee Stock Option Exercise	Aerovate Therapeutics, Inc.		7871	04/02/2021 N/A

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
Benjamin T Dake PhD 930 Winter Street, Suite M-500 Waltham MA 02451	Common	03/06/2023	10282	243953.71
Benjamin T Dake PhD 930 Winter Street, Suite M-500 Waltham MA 02451	Common	04/06/2023	10283	186828.54

# 144: Remarks and Signature

Remarks

Date of Notice 05/08/2023

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 04/14/2022

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Benjamin T Dake

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)